Study to Evaluate the Efficacy and Safety of DS-1971a for the Treatment of Diabetic Peripheral Neuropathic Pain (DPNP)
Status:
Withdrawn
Trial end date:
2017-02-01
Target enrollment:
Participant gender:
Summary
The hypothesis of this Phase 2 study is that at least 1 dose regimen of DS-1971a will
demonstrate clinical superiority to placebo in managing pain associated with DPNP, and will
be generally well tolerated.